191 related articles for article (PubMed ID: 16291425)
1. Advances in the treatment of second-line non-small-cell lung cancer.
Hanna N
Lung Cancer; 2005 Oct; 50 Suppl 1():S15-7. PubMed ID: 16291425
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Tiseo M
J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
[TBL] [Abstract][Full Text] [Related]
3. The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer.
Tucker S
Curr Drug Targets; 2010 Jan; 11(1):58-60. PubMed ID: 19839927
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed in second-line treatment of non-small-cell lung cancer.
De Marinis F; De Petris L
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):38-42. PubMed ID: 15655935
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.
Hanna NH
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S75-9. PubMed ID: 15117429
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer.
Georgoulias VA
Lung Cancer; 2002 Dec; 38 Suppl 3():S61-6. PubMed ID: 12468149
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
Scagliotti GV
Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
de Marinis F; De Santis S; De Petris L
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S17-24. PubMed ID: 16472705
[TBL] [Abstract][Full Text] [Related]
16. Antimetabolites in the management of non-small cell lung cancer.
Budde LS; Hanna NH
Curr Treat Options Oncol; 2005 Jan; 6(1):83-93. PubMed ID: 15610718
[TBL] [Abstract][Full Text] [Related]
17. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
18. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
Weiss GJ; Rosell R; Fossella F; Perry M; Stahel R; Barata F; Nguyen B; Paul S; McAndrews P; Hanna N; Kelly K; Bunn PA
Ann Oncol; 2007 Mar; 18(3):453-60. PubMed ID: 17322539
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
